Canaccord Genuity Maintains a 'Hold' on AspenBio Pharma (AAPY); Multi-marker Panel Likely Key to Approval & Uptake
Tweet
Share
E-mailGet Alerts APPY Hot Sheet
Price: $3.94 --0%
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on AspenBio Pharma (NASDAQ: APPY) price target of $2.50.
Analyst, Jeffrey Frelick, said, "We are refreshing our AppyScore timelines and expectations following a recent management update and the completion of its validation study. Last month APPY revealed strong pilot data, which included a new multi-marker panel of MRP 8/14, CRP, and WBC, that provided superior results compared to prior clinical studies. We believe the path to approval and commercialization for the AppyScore appendicitis test has improved significantly. We maintain our HOLD for now, as we await the commencement of the pivotal study next quarter."
For an analyst ratings summary and ratings history on AspenBio Pharma click here. For more ratings news on AspenBio Pharma click here.
Shares of AspenBio Pharma closed at $0.96 yesterday.
Analyst, Jeffrey Frelick, said, "We are refreshing our AppyScore timelines and expectations following a recent management update and the completion of its validation study. Last month APPY revealed strong pilot data, which included a new multi-marker panel of MRP 8/14, CRP, and WBC, that provided superior results compared to prior clinical studies. We believe the path to approval and commercialization for the AppyScore appendicitis test has improved significantly. We maintain our HOLD for now, as we await the commencement of the pivotal study next quarter."
For an analyst ratings summary and ratings history on AspenBio Pharma click here. For more ratings news on AspenBio Pharma click here.
Shares of AspenBio Pharma closed at $0.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades Crown Castle (CCI) to Overweight
- UBS Upgrades SLC Agricola SA (SLCE3:BZ) (SLCJY) to Neutral
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
